iSpecimen Q2 EPS $(0.39) Misses $(0.30) Estimate, Sales $1.63M Miss $3.07M Estimate
Portfolio Pulse from Benzinga Newsdesk
iSpecimen reported Q2 losses of $0.39 per share, missing the analyst consensus estimate of $0.30 by 30%. The company's quarterly sales were $1.63 million, missing the estimate of $3.07 million by 47.07%. This represents a 30.53% decrease in sales compared to the same period last year.
August 04, 2023 | 10:55 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
iSpecimen's Q2 earnings missed estimates, with a larger loss per share and lower sales than expected. This could negatively impact the company's stock price in the short term.
iSpecimen's Q2 earnings were lower than expected, with a larger loss per share and lower sales than analysts' estimates. This underperformance could lead to a decrease in the company's stock price in the short term as it indicates potential financial instability.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100